Elixir Medical Highlights Results From “Real World” MY-IVL Study Demonstrating Performance of LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Treating Calcified Coronary Lesions
Elixir Medical announced results from the MY-IVL Study at the TCT Conference 2025 that demonstrate performance of Lithix™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in treating heart disease.
Elixir Medical Announces Key Commercial Milestone With LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL)
Elixir Medical announces key commercial milestone with LithiX™ HC-IVL, a novel lithotripsy system designed to facilitate treatment of heart disease exacerbated by the presence of calcium within coronary artery plaques. New clinical study to be presented at TCT Conference 2025.
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX® Bioadaptor Over Drug-Eluting Stent Through Three Years
Late-breaking data demonstrate sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) and significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with DynamX® compared to DES.
Elixir Medical Announces Launch of LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Europe
Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary artery lesions without requiring an energy source. IVL technology expands company’s innovative product portfolio.
Elixir Medical Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025
Elixir Medical’s LithiX HC-IVL system data demonstrate sustained safety and efficacy at six months, as reported at the TCT conference.
Elixir Medical’s LithiX HC-IVL System Data Demonstrate Sustained Safety and Efficacy at Six Months
Elixir Medical’s LithiX HC-IVL system data demonstrate sustained safety and efficacy at six months, as reported at the TCT conference.
Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
—Late-breaking 12-month data from INFINITY-SWEDEHEART presented at TCT 2024 further validate bioadaptor’s unique mechanism of action in complex PCI population subsets— —Results of INFINITY-SWEDEHEART trial published in The Lancet— Washington D.C. – October 28, 2024 – Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced late-breaking data demonstrating significant benefit of […]
TCT 2024: Elixir Medical to Present Clinical Outcomes on Two Transformative Platforms Designed to Advance Cardiovascular Disease Treatment and Intervention
Late-breaking INFINITY-SWEDEHEART Randomized Clinical Trial (RCT) data evaluating DynamX® Coronary Bioadaptor System’s unique mechanism of action among patients with Acute Coronary Syndrome (ACS) and complex lesion subsets.
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action
Largest randomized data set to date on bioadaptor, with a complex patient population of 2,400 compared to a DES. Primary endpoint of target lesion failure (TLF) non-inferiority at twelve months was met with a low event rate for DynamX despite increased patient complexity.
Elixir Medical to Present Late-Breaking One-Year Primary Outcomes from the 2,400 Patient INFINITY-SWEDEHEART Clinical Trial at ESC Congress 2024
Elixir Medical is presenting one-year clinical outcomes from the 2,400 patient INFINITY-SWEDEHEART Randomized Clinical Trial (RCT) at ESC Congress 2024 in London.